AU2017357785A1 - Methods and compositions for treatment of cartilage damage and arthritis - Google Patents

Methods and compositions for treatment of cartilage damage and arthritis Download PDF

Info

Publication number
AU2017357785A1
AU2017357785A1 AU2017357785A AU2017357785A AU2017357785A1 AU 2017357785 A1 AU2017357785 A1 AU 2017357785A1 AU 2017357785 A AU2017357785 A AU 2017357785A AU 2017357785 A AU2017357785 A AU 2017357785A AU 2017357785 A1 AU2017357785 A1 AU 2017357785A1
Authority
AU
Australia
Prior art keywords
polypeptide
composition
amino acid
seq
intra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017357785A
Other languages
English (en)
Other versions
AU2017357785A2 (en
Inventor
Jorg Goldhahn
Kristen Johnson
Celeste SCOTTI
Igor Vostiar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2017357785A1 publication Critical patent/AU2017357785A1/en
Publication of AU2017357785A2 publication Critical patent/AU2017357785A2/en
Priority to AU2020281098A priority Critical patent/AU2020281098B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017357785A 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis Abandoned AU2017357785A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020281098A AU2020281098B2 (en) 2016-11-14 2020-12-03 Methods and compositions for treatment of cartilage damage and arthritis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662421534P 2016-11-14 2016-11-14
US62/421,534 2016-11-14
US201762560301P 2017-09-19 2017-09-19
US62/560,301 2017-09-19
PCT/IB2017/057081 WO2018087727A1 (en) 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020281098A Division AU2020281098B2 (en) 2016-11-14 2020-12-03 Methods and compositions for treatment of cartilage damage and arthritis

Publications (2)

Publication Number Publication Date
AU2017357785A1 true AU2017357785A1 (en) 2019-04-11
AU2017357785A2 AU2017357785A2 (en) 2019-05-02

Family

ID=60629753

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017357785A Abandoned AU2017357785A1 (en) 2016-11-14 2017-11-13 Methods and compositions for treatment of cartilage damage and arthritis
AU2020281098A Active AU2020281098B2 (en) 2016-11-14 2020-12-03 Methods and compositions for treatment of cartilage damage and arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020281098A Active AU2020281098B2 (en) 2016-11-14 2020-12-03 Methods and compositions for treatment of cartilage damage and arthritis

Country Status (10)

Country Link
US (3) US11351223B2 (enExample)
EP (1) EP3538127A1 (enExample)
JP (2) JP2019535707A (enExample)
KR (2) KR20240045351A (enExample)
CN (2) CN109963579A (enExample)
AU (2) AU2017357785A1 (enExample)
CA (1) CA3043667A1 (enExample)
IL (1) IL266361B2 (enExample)
MX (2) MX2019005621A (enExample)
WO (1) WO2018087727A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117355323A (zh) 2021-05-24 2024-01-05 诺华股份有限公司 用于治疗骨关节炎的方法
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
WO2023084388A1 (en) * 2021-11-10 2023-05-19 Novartis Ag Methods for determining the biological activity of angptl polypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
MXPA05003983A (es) 2002-10-16 2005-06-22 Scripps Research Inst Incorporacion en sitio especifico de cetoaminoacidos en proteinas.
EP1558747B1 (en) 2002-10-16 2009-10-14 The Scripps Research Institute Glycoprotein synthesis
JP5642916B2 (ja) 2003-04-17 2014-12-17 ザ スクリプス リサーチ インスティテュート 真核遺伝コードの拡張
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
EP1704242A4 (en) 2003-07-07 2008-06-18 Scripps Research Inst COMPOSITIONS WITH PAIRS OF ORTHOGONAL LEUCYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
MX2007003142A (es) 2004-09-21 2007-07-04 Scripps Research Inst Incorporacion in vivo de alquinil aminoacidos a proteinas en eubacterias.
MX2007004892A (es) 2004-10-27 2007-08-16 Scripps Research Inst Componentes de traduccion ortogonales para la incorporacion in vivo de aminoacidos no naturales.
MX2008011470A (es) 2006-03-09 2008-09-24 Scripps Research Inst Sistemas para la expresion de componentes de traduccion ortogonales en celulas huesped eubacterianas.
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
CA2746395C (en) * 2008-12-10 2019-07-09 Ablynx N.V. Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
PE20160507A1 (es) * 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US9301971B2 (en) * 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
EP2968330B1 (en) * 2013-03-15 2021-09-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
HRP20241236T1 (hr) * 2014-05-13 2024-12-06 Novartis Ag Spojevi i pripravci za induciranje hondrogeneze

Also Published As

Publication number Publication date
MX2022011897A (es) 2022-10-18
CN117860868A (zh) 2024-04-12
AU2020281098A1 (en) 2021-01-14
JP2019535707A (ja) 2019-12-12
US20250302915A1 (en) 2025-10-02
RU2019117884A (ru) 2020-12-14
AU2020281098B2 (en) 2024-05-02
MX2019005621A (es) 2019-08-12
US20220331398A1 (en) 2022-10-20
RU2019117884A3 (enExample) 2021-02-05
CA3043667A1 (en) 2018-05-17
US11351223B2 (en) 2022-06-07
CN109963579A (zh) 2019-07-02
WO2018087727A1 (en) 2018-05-17
IL266361B1 (en) 2023-10-01
IL266361A (en) 2019-06-30
US20190269754A1 (en) 2019-09-05
KR20190084287A (ko) 2019-07-16
KR20240045351A (ko) 2024-04-05
EP3538127A1 (en) 2019-09-18
JP2023039962A (ja) 2023-03-22
IL266361B2 (en) 2024-02-01
AU2017357785A2 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
US11179442B2 (en) Peptides and compositions for treatment of joint damage
US20250302915A1 (en) Methods and compositions for treatment of cartilage damage and arthritis
US20220402987A1 (en) Peptides and compositions for treatment of joint damage
RU2777504C2 (ru) Способы и композиции для лечения повреждения хряща и артрита
HK1260928A1 (en) Peptides and compositions for treatment of joint damage
HK1214754B (en) Peptides and compositions for treatment of joint damage

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 12 APR 2019

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted